Paul Hodgkins, PhD, MSc

Number Needed to Treat Analysis of the SAGE-217 Phase 2 Clinical Trial Results in Major Depressive Disorder

Background: SAGE-217 is a novel, positive allosteric modulator of GABA(A) receptors under development in Major Depressive Disorder (MDD). This analysis quantified the number needed to tre...

Ken O'Day , PhD, MPA;

Vijayveer Bonthapally , PhD;

Alix Arnaud , MSc;

Ellison Suthoff , MBA, BS ;

Katie Stenson , MSc;

Brian Werneburg , PhD;

Paul Hodgkins , PhD, MSc;

Jeffrey Jonas , MD;

Kellie Meyer , PharmD, MPH;

11/22/2019

Evaluating Pharmacotherapies for Postpartum Depression: A Comparison of SSRIs to Brexanolone Injection, A Novel Investigational Compound

Objective: In randomized controlled trials (RCTs) in women with postpartum depression (PPD), 60 hours of continuous brexanolone infusion (90mg/kg) was associated with significant reductio...

Miranda Cooper , MSc, BSc;

Hannah Kilvert , MSc;

Adi Eldar-Lissai , PhD;

Paul Hodgkins , PhD, MSc;

Neil Roskell , MSc;

03/01/2019